Brazilian startup advances strategic collaborations to drive new therapies and support the development of precision medicine

gen-t, the startup developing the largest and most diverse genetic bank in Latin America, is now officially open for partnerships with the pharmaceutical and biotech sectors. The goal is to drive innovation in the development of new treatments based on its diverse genome.

After reaching 10,000 participants across Brazil, gen-t’s genetic bank is ready to support the industry in developing precision medicine, leveraging the rich diversity of the Brazilian population—a genetic mosaic offering unique combinations not yet explored by the R&D departments of the pharmaceutical market.

Gen-t’s infrastructure allows partners from the pharmaceutical and biotech sectors to conduct targeted recruitment of specific population groups and access health data, lifestyle information, and DNA and plasma samples stored in its biobank for groundbreaking research.

“The genetic diversity in Brazil is unparalleled globally, positioning the country as a leader in scientific discoveries that can revolutionize precision medicine,” says Lygia V. Pereira, founder and CEO of gen-t, and professor of Human Genetics at the University of São Paulo (USP). “We are excited about the opportunity to collaborate with companies that share our vision of creating more effective, specific, and personalized treatments for all populations.”

gen-t offers interested companies the opportunity to use this vast genetic database to conduct research that could lead to significant advances in the treatment of diseases, particularly those affecting underrepresented populations in traditional genetic studies, which are predominantly based on databases from white and European populations.

“Brazil, with its unique ethnic blend, has the potential to fill critical gaps in global research, offering solutions that could benefit health on a global scale,” adds Fernando Stegmann, co-founder of gen-t.

Brazil’s genetic bank is now officially open to discussions with companies interested in developing innovative precision medicines.